Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients.
Zaltzman
J
J
St Michael's Hospital, Toronto, Ontario, Canada.
McAlister
V
V
Russell
D
D
Halloran
P
P
Landsberg
D
D
Busque
S
S
Shoker
A
A
Boucher
A
A
Shapiro
J
J
Tchervenkov
J
J
Peets
J
J
D000208:Acute Disease; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus